Albert Labs Chief Commercial Officer Graeme Mcfarlane joins Proactive London's Katie Pilbeam to talk about their upcoming listing which he says will be a 'good vehicle for us to attract investment capital' and deliver on their promise to provide their treatments to patients in need.
Albert Labs is the first psychedelic company leveraging Real World Evidence Studies to enhance patient care by accelerating access to psychedelic therapy in a hospital setting for niche indications with urgent and high unmet needs.
He says it's all about 'making a difference' and aims to fill the gap where certain patients are not getting access to this treatment that he believes they so desperately need, such as cancer victims who are now dealing with mental health issues as a consequence.